Discovery of New Circulating Biomarkers of Coronary Atherosclerosis
NCT ID: NCT00430820
Last Updated: 2010-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
124 participants
OBSERVATIONAL
2007-03-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
Primary objective: Identification of new circulating biomarkers of stable and unstable coronary artery disease using a new approach of differential proteomics.
Secondary objectives:
* Evaluation of the diagnostic value of these new biomarkers for the diagnosis of stable and unstable coronary artery disease.
* Comparison of the diagnostic value of these new biomarkers to the diagnostic value of 1) other validated biomarkers of atherosclerosis (eg, CRP, IL-6, CD40L, markers of leukocyte activation, …); and 2) of non-invasive measures of arterial function (eg, carotid artery intima-media thickness, pulse wave velocity, ankle/brachial index, …)
* Description of the relationship between these new biomarkers and major adverse coronary events (death, myocardial infarction, revascularization) during a 12-month follow-up.
Methods:
Uniq center, prospective study. Three groups of patients will be studied. Group 1: Non-ST-elevation acute myocardial infarction; Group 2: Stable coronary artery disease; Group 3: normal coronary arteries and absence of other detectable atherosclerotic lesions.
A new proteomic approach will be applied to serum and plasma samples obtained 1 month after the index hospitalisation. This approach includes 3 steps: 1) equalisation of circulating proteins (expose low-concentration proteins belonging to the "deep-proteome"); 2) Retention chromatography; and 3) protein separation using 2D-electrophoresis and Surface-Enhanced Laser Desorption/Ionisation Time-of-Flight (SELDI-TOF).
Biomarkers with the highest diagnostic value will be subsequently identified using Matrix-Assisted Laser Desorbtion/Ionisation Time-of-Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS).
Perspectives:
Validation of the diagnostic and prognostic values of the new biomarkers discovered and identified using the proteomic approach described above will require development of more straightforward measurement techniques (eg, ELISA), which will be used prospectively or retrospectively in other cohorts of patients with coronary artery disease. Basic studies will be performed in parallel, so as to better understand the role of these new biomarkers in the pathophysiology of atherosclerosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
30 patients
per intervention
per intervention
2
30 patients
per intervention
per intervention
3
30 patients
per intervention
per intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
per intervention
per intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chest pain less than 48 hours before admission,
* And modifications of ST-T (no persistent ST elevation) on 12-lead EKG,
* And elevation of troponin-I \>1xN,
* And presence of ≥1 de novo stenosis(es) \>50% located on ≥1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
* Group 2 (Stable coronary artery disease) :
* Documented myocardial ischemia (stable angina or positive stress test)
* And presence of ≥1 de novo stenosis(es) \>50% located on ≥1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
* Group 3 (Normal coronary arteries) :
* No history of coronary artery disease, neurovascular disease or peripheral artery disease,
* And normal coronary angiography performed because of suspected coronary artery disease
* And absence of significant functional or anatomic abnormalities suggestive of atherosclerosis on non-invasive arterial studies (measurements of intima-media thickness, pulse wave velocity, ankle-brachial index, …).
Exclusion Criteria
* Preexisting EKG abnormalities (including left bundle branch block) precluding accurate assessment of ST-T changes
* Group 2 :
* History of acute coronary syndrome
* Groups 1 and 2:
* Culprit coronary artery stenosis is a restenosis or a stent thrombosis or is located in a bypass graft.
* All groups :
* Heart failure (NYHA class ≥II)
* Left ventricular ejection fraction \<50%
* Severe valvular heart disease requiring surgical or percutaneous therapy
* History of autoimmune, inflammatory or neoplasia diseases ; or infectious disease in the month before admission
* Life expectancy \< 1 year
* Age \<18 years or \>80 years
* Current pregnancy or breast-feeding
* Homeless or travelers who may not be followed-up
* Refusal to sign the informed consent form
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fédération Française de Cardiologie
OTHER
Société Française de Cardiologie
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department Clinical Research of Developppement
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurent FELDMAN, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Hopital Bichat, APHP
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Duran MC, Mas S, Martin-Ventura JL, Meilhac O, Michel JB, Gallego-Delgado J, Lazaro A, Tunon J, Egido J, Vivanco F. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 2003 Jun;3(6):973-8. doi: 10.1002/pmic.200300389.
Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tunon J, Vivanco F, Egido J. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004 Oct 12;110(15):2216-9. doi: 10.1161/01.CIR.0000136814.87170.B1. Epub 2004 Jul 12.
Vivanco F, Martin-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L, Darde VM, Mas S, Meilhac O, Michel JB, Tunon J, Egido J. Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res. 2005 Jul-Aug;4(4):1181-91. doi: 10.1021/pr0500197.
Blanco-Colio LM, Martin-Ventura JL, Vivanco F, Michel JB, Meilhac O, Egido J. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res. 2006 Oct 1;72(1):18-29. doi: 10.1016/j.cardiores.2006.05.017. Epub 2006 May 24.
Ramos-Mozo P, Madrigal-Matute J, Vega de Ceniga M, Blanco-Colio LM, Meilhac O, Feldman L, Michel JB, Clancy P, Golledge J, Norman PE, Egido J, Martin-Ventura JL. Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm. Atherosclerosis. 2012 Feb;220(2):552-6. doi: 10.1016/j.atherosclerosis.2011.11.023. Epub 2011 Nov 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P060201
Identifier Type: -
Identifier Source: org_study_id